Focused allergic rhinitis practice parameter for Canada

Simple item page
dc.contributor.authorEllis, Anne K.
dc.contributor.authorCook, Victoria
dc.contributor.authorKeith, Paul K.
dc.contributor.authorMace, Sean R.
dc.contributor.authorMoote, William
dc.contributor.authorO’Keefe, Andrew
dc.contributor.authorQuirt, Jaclyn
dc.contributor.authorRosenfield, Lana
dc.contributor.authorSmall, Peter
dc.contributor.authorWatson, Wade
dc.date.accessioned2024-09-03T14:36:27Z
dc.date.available2024-09-03T14:36:27Z
dc.date.issued2024-08-08
dc.date.updated2024-09-01T03:22:03Z
dc.description.abstractAllergic rhinitis (AR) is a prevalent disease in Canada that affects both children and adults. Several guidelines for the management of AR have been published by professional allergy societies worldwide. However, there are regional differences in the clinical management of AR, and regulatory approval of some AR pharmacotherapies varies among countries. Thus, six research questions specific to the treatment of AR in Canada were identified for this focused practice parameter. Reviews of the literature published since 2016 were conducted to obtain evidence-based support for the responses of the Work Group to each research question. In response to research question 1 “In patients with symptoms indicative of AR, is serum-specific IgE sufficient to identify candidates for immunotherapy or is a skin prick test mandatory?” the Work Group concluded that either sIgE testing or skin prick test are acceptable for diagnosing AR and guiding immunotherapy. In response to research question 2 “When taking into account the preferences of the patient and the prescriber (stakeholder engagement) should second-generation oral antihistamine (OAH) or intranasal corticosteroid (INCS) be first line?” the Work Group concluded that existing guidelines generally agree on the use of INCS as a first-line therapy used for AR, however, patient and provider preferences and considerations can easily shift the first choice to a second-generation OAH. In response to research question 3 “Is a combination intranasal antihistamine (INAH)/INCS formulation superior to INCS plus OAH? Do they become equivalent after prolonged use?” the Work Group concluded that that the combination INAH/INCS is superior to an INCS plus OAH. However, there was insufficient evidence to answer the second question. In response to research question 4 “Do leukotriene receptor antagonists (LTRA) have a greater benefit than OAH in AR for some symptoms to justify a therapeutic trial in those who cannot tolerate INCS?” the Work Group concluded that LTRAs have inferior, or at best equivalent, daytime or overall symptom control compared with OAH, but LTRAs may improve nighttime symptom control and provide benefits in patients with AR and concomitant asthma. In response to research question 5 “Should sublingual immunotherapy (SLIT) tablets be considered first-line immunotherapeutic options over subcutaneous immunotherapy (SCIT) based on the evidence of efficacy?” the Work Group concluded that the choice of SLIT or SCIT cannot be made on efficacy alone, and differences in other factors outweigh any differences in efficacy. In response to research question 6 “Based on efficacy data, should ALL patients seen by an allergist be offered SLIT or SCIT as a treatment option?” the Work Group concluded that the efficacy data suggests that SLIT or SCIT should be used broadly in patients with AR, but other clinical concerns also need to be taken into consideration.
dc.identifier.citationAllergy, Asthma & Clinical Immunology. 2024 Aug 08;20(1):45
dc.identifier.doi10.1186/s13223-024-00899-3
dc.identifier.urihttp://hdl.handle.net/1993/38486
dc.language.isoeng
dc.language.rfc3066en
dc.publisherBMC
dc.rightsopen accessen_US
dc.rights.holderThe Author(s)
dc.titleFocused allergic rhinitis practice parameter for Canada
dc.typeJournal Article
local.author.affiliationRady Faculty of Health Sciences::Max Rady College of Medicine::Department of Internal Medicine
oaire.citation.issue45
oaire.citation.titleAllergy, Asthma & Clinical Immunology
oaire.citation.volume20
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13223_2024_Article_899.pdf
Size:
2.19 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
770 B
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works